Camelia Gliser

4.1k total citations
27 papers, 716 citations indexed

About

Camelia Gliser is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Camelia Gliser has authored 27 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 16 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Camelia Gliser's work include Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Camelia Gliser is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Camelia Gliser collaborates with scholars based in United States, United Kingdom and Spain. Camelia Gliser's co-authors include Shuchi S. Pandya, Liewen Jiang, Katharine Yen, Sam Agresta, Bin Wu, Jeremy Travins, Ghassan K. Abou‐Alfa, Andrew X. Zhu, Hua Yang and Maeve A. Lowery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Camelia Gliser

24 papers receiving 706 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Camelia Gliser United States	12	303	242	241	227	195	27	716
Max M. van Noesel Netherlands	16	445 1.5×	133 0.5×	291 1.2×	169 0.7×	232 1.2×	44	1.0k
Kerry D. Lynch United States	6	352 1.2×	137 0.6×	285 1.2×	233 1.0×	319 1.6×	7	887
Hayley Robinson United States	6	308 1.0×	90 0.4×	233 1.0×	230 1.0×	307 1.6×	8	718
Kenneth J. Craddock Canada	12	162 0.5×	84 0.3×	261 1.1×	163 0.7×	250 1.3×	28	618
Joana Vieira Portugal	14	344 1.1×	85 0.4×	220 0.9×	134 0.6×	293 1.5×	39	701
Michael Considine United States	17	484 1.6×	120 0.5×	280 1.2×	244 1.1×	135 0.7×	42	836
Daniela Graziani Italy	11	284 0.9×	248 1.0×	393 1.6×	107 0.5×	163 0.8×	23	767
Arnaud Lagarde France	14	506 1.7×	74 0.3×	243 1.0×	164 0.7×	102 0.5×	27	927
Troy Bainbridge United States	7	232 0.8×	247 1.0×	190 0.8×	55 0.2×	512 2.6×	7	1.1k
W. M. Linehan United States	7	243 0.8×	150 0.6×	125 0.5×	229 1.0×	359 1.8×	12	690

Countries citing papers authored by Camelia Gliser

Since Specialization

Citations

This map shows the geographic impact of Camelia Gliser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camelia Gliser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camelia Gliser more than expected).

Fields of papers citing papers by Camelia Gliser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camelia Gliser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camelia Gliser. The network helps show where Camelia Gliser may publish in the future.

Co-authorship network of co-authors of Camelia Gliser

This figure shows the co-authorship network connecting the top 25 collaborators of Camelia Gliser. A scholar is included among the top collaborators of Camelia Gliser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camelia Gliser. Camelia Gliser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

El-Khoueiry, Anthony B., et al.. (2026). Results from the safety lead-in for a phase 1b/2 study of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 44(2_suppl). 558–558.

Harding, James J., Anthony B. El-Khoueiry, Hong Jae Chon, et al.. (2025). A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 43(16_suppl).

Kelley, Robin Kate, James M. Cleary, Vaibhav Sahai, et al.. (2024). A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4197–TPS4197. 1 indexed citations

Fan, Bin, Ghassan K. Abou‐Alfa, Andrew X. Zhu, et al.. (2024). Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. Cancer Chemotherapy and Pharmacology. 93(5). 471–479. 4 indexed citations

Valle, Juan W., Ghassan K. Abou‐Alfa, Robin Kate Kelley, et al.. (2023). SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial. Annals of Oncology. 34. S162–S162.

Chamberlain, Christina X., Zhaowei Hua, Camelia Gliser, et al.. (2022). Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.. Journal of Clinical Oncology. 40(4_suppl). 388–388. 2 indexed citations

Valle, Juan W., Teresa Macarulla, Milind Javle, et al.. (2022). 552 Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial. Regular and Young Investigator Award Abstracts. A576–A577. 1 indexed citations

Zhu, Andrew X., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(3_suppl). 266–266. 38 indexed citations

Abou‐Alfa, Ghassan K., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(15_suppl). 4069–4069. 1 indexed citations

10.

Abou‐Alfa, Ghassan K., Andrew X. Zhu, Teresa Macarulla, et al.. (2020). IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.. Journal of Clinical Oncology. 38(15_suppl). 4576–4576. 19 indexed citations

11.

Fan, Bin, Ghassan K. Abou‐Alfa, Andrew X. Zhu, et al.. (2020). Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.. Journal of Clinical Oncology. 38(4_suppl). 539–539. 3 indexed citations

12.

Fan, Bin, Ingo K. Mellinghoff, Patrick Y. Wen, et al.. (2019). Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs. 38(2). 433–444. 71 indexed citations

13.

Aguado-Fraile, Elia, Sung Choe, Camelia Gliser, et al.. (2019). Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma. Cancer Research. 79(13_Supplement). 2275–2275. 2 indexed citations

14.

Abou‐Alfa, Ghassan K., T. Macarulla Mercadé, Milind Javle, et al.. (2019). ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology. 30. v872–v873. 69 indexed citations

15.

Abou‐Alfa, Ghassan K., Juan W. Valle, Robin Kate Kelley, et al.. (2018). ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 36(4_suppl). TPS545–TPS545. 6 indexed citations

16.

Shih, Alan H., Cem Meydan, Kaitlyn Shank, et al.. (2017). Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia. Cancer Discovery. 7(5). 494–505. 71 indexed citations

17.

Lowery, Maeve A., Ghassan K. Abou‐Alfa, Juan W. Valle, et al.. (2017). ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 35(15_suppl). TPS4142–TPS4142. 11 indexed citations

18.

Hansen, Erica, Cyril Quivoron, René M. Lemieux, et al.. (2014). AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. Blood. 124(21). 3734–3734. 40 indexed citations

19.

Kernytsky, Andrew, Fang Wang, Erica Hansen, et al.. (2014). IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 125(2). 296–303. 128 indexed citations

20.

Kernytsky, Andrew, Fang Wang, Erica Hansen, et al.. (2014). Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition. Cancer Research. 74(19_Supplement). 2296–2296. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact